Immatics (NASDAQ:IMTX - Get Rating) - Analysts at Chardan Capital boosted their FY2022 earnings estimates for Immatics in a report issued on Monday, November 21st. Chardan Capital analyst Y. Livshits now expects that the company will earn $0.81 per share for the year, up from their prior forecast of $0.23. Chardan Capital has a "Buy" rating and a $28.00 price target on the stock. The consensus estimate for Immatics' current full-year earnings is $0.44 per share. Chardan Capital also issued estimates for Immatics' FY2023 earnings at ($1.31) EPS.
Immatics Price Performance
Shares of NASDAQ IMTX opened at $9.94 on Thursday. The firm has a fifty day moving average price of $10.46 and a 200-day moving average price of $9.89. The stock has a market cap of $757.70 million, a PE ratio of 14.84, a price-to-earnings-growth ratio of 1.84 and a beta of 0.48. Immatics has a 1 year low of $5.75 and a 1 year high of $14.00.
Institutional Trading of Immatics
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nantahala Capital Management LLC increased its stake in shares of Immatics by 6.0% in the second quarter. Nantahala Capital Management LLC now owns 3,121,759 shares of the company's stock worth $27,191,000 after purchasing an additional 177,100 shares in the last quarter. Alyeska Investment Group L.P. increased its stake in shares of Immatics by 1.6% in the first quarter. Alyeska Investment Group L.P. now owns 1,409,495 shares of the company's stock worth $11,262,000 after purchasing an additional 21,883 shares in the last quarter. Millennium Management LLC increased its stake in shares of Immatics by 1,414.3% in the second quarter. Millennium Management LLC now owns 566,752 shares of the company's stock worth $4,936,000 after purchasing an additional 529,325 shares in the last quarter. Silverarc Capital Management LLC increased its stake in shares of Immatics by 13.9% in the first quarter. Silverarc Capital Management LLC now owns 445,334 shares of the company's stock worth $3,558,000 after purchasing an additional 54,179 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Immatics in the third quarter worth $2,437,000. 34.12% of the stock is owned by hedge funds and other institutional investors.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here